ISRCTN ISRCTN95606674
DOI https://doi.org/10.1186/ISRCTN95606674
Secondary identifying numbers 1.0
Submission date
05/01/2017
Registration date
10/01/2017
Last edited
09/01/2017
Recruitment status
No longer recruiting
Overall study status
Ongoing
Condition category
Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Platelets are the component of blood which helps the blood to clot. A low platelet count can cause bleeding and bruising which can sometimes be serious. There are many different causes and treatments depend on the cause. It is not always easy for doctors to diagnose the cause and often many investigations are needed including uncomfortable bone marrow biopsy tests. In addition, even when the cause is known, different treatments may be tried before finding one that works. Some of the treatments used may have side effects and it would be helpful to develop blood tests that would predict which medicines will make which patients better. This would help treatment to be individualised, speeding up the time to get better and avoiding side effects of treatments that don't work. This study aims to develop new laboratory test to help with the diagnosis, identification of how the disease is working and prediction of treatment response in patients with low platelet counts.

Who can participate?
Patients aged 16 years and over who have a low platelet count and are in need of treatment.

What does the study involve?
During routine hospital appointments, patients with low platelet counts are asked if they are happy to provide an extra sample of blood when having routine blood tests. The blood samples are then sent to different laboratory studies so that new tests can be developed to help with the diagnosis, identification of how the disease is working and prediction of treatment response in patients with low platelet counts.

What are the possible benefits and risks of participating?
There are no direct benefits or risks involved with participating.

Where is the study run from?
Bristol Haematology and Oncology Centre (UK)

When is the study starting and how long is it expected to run for?
January 2015 to March 2018

Who is funding the study?
Above and Beyond (UK)

Who is the main contact?
Dr Charlotte Bradbury
c.bradbury@bristol.ac.uk

Contact information

Dr Charlotte Bradbury
Scientific

Bristol Haematology and Oncology Centre
Horfield Road
Bristol
BS28ED
United Kingdom

ORCiD logoORCID ID 0000-0001-5248-8165
Phone +44 117 342 1113
Email c.bradbury@bristol.ac.uk

Study information

Study designObservational cohort study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeOther
Scientific titleThe development of laboratory assays for patients with low platelet counts to help predict treatment responses
Study hypothesisThe aim of this study is to develop new laboratory tests to assist with diagnosis, identification of disease mechanism and prediction of treatment response in patients with low circulating platelet counts.
Ethics approval(s)South East Coast - Brighton and Sussex NRES Committee, 30/11/2015, ref: 15/LO/2088
ConditionThrombocytopenia
InterventionThere will be no additional hospital appointments or venepunctures done specifically for this research. During a routine hospital appointment, each participant will be given patient information and the opportunity to ask questions. They will then be asked to given written consent. Following consent, when they are having other bloods done we will take extra blood samples for research (maximum of 50ml). The consent procedure is estimated to take 30 mins and is done by the Consultant in charge of their haematology condition. The samples will be anonymised and sent to different laboratory’s in Bristol for different assays: NHS BT Filton for antibody assays, North Bristol haematology laboratory for lymphocyte subsets, UH Bristol haematology laboratory for platelet counting and ROTEM if done and University of Bristol research laboratory’s for short term lymphocyte culture experiments. DNA may also be stored in a secure -70 freezer on level 8 BRI.

Patients may be asked to give further samples (maximum of 3 times per year).

Patients will receive standard treatments according to their condition and treatment responses (bleeding episodes, platelet count data, side effects) will be anonymised and recorded on a secure database. The results of laboratory assays will be correlated with clinical data over a minimum of 12 months.
Intervention type
Primary outcome measureCandidate biomarkers of clinical response are assessed by evaluating the correlation of laboratory assay results to clinical response data (bleeding and platelet count data over at least 12 months, the latter will be collected from routine blood tests done on patients according to clinical need).
Secondary outcome measuresPositive and negative predictive value of some assays to specific causes of low platelet count and discrepancy of results from different types of assay used to measure low platelet counts.
Overall study start date07/03/2016
Overall study end date05/01/2026

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit16 Years
SexBoth
Target number of participants100
Participant inclusion criteria1. Age range >16 years old
2. Male and female
3. Low platelet count AND need for treatment
4. Hb>100g/l
Participant exclusion criteria1. Hb<100g/L
2. Patients unable to consent (e.g. due to mental incapacity)
Recruitment start date07/03/2016
Recruitment end date05/01/2025

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Bristol Haematology and Oncology Centre
University Hospital Bristol
Horfield Road
Bristol
BS2 8ED
United Kingdom

Sponsor information

University of Bristol
University/education

Tyndall Avenue
Bristol
BS81TH
England
United Kingdom

ROR logo "ROR" https://ror.org/0524sp257

Funders

Funder type

Charity

Above and Beyond

No information available

Results and Publications

Intention to publish date05/01/2027
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planPlanned presentation of the research findings at international meetings and publish them in high-impact peer reviewed journals. It is expected that some interim results be ready within 3 years by 2020. In addition, a plain English summary of the research findings will be published in “the platelet” a monthly magazine from the ITP support association (a patient and public group).
IPD sharing planThis study will generate numerous sets of complex data for different elements of this study. The remit of the study is broad, and aims to generate pilot data to be validated prospectively in future clinical trials. Due to the complexity of the data generated, at present we cannot guarantee we will be able to make available participant level data but we do plan to generate a plain English summary of the main research findings when available. The anonymised data will be stored securely.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No